NMRA on Nasdaq

Neumora Therapeutics, Inc.

Biopharmaceutical company.1

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerNMRA on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersWatertown, Massachusetts1
  • Websiteneumoratx.com
  • Incorporated inDE3
  • Business address260 Arsenal Place, Suite 1, Watertown, Ma 024723
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by bringing forward the next generation of novel therapies with brain-penetrant chemistry that offer improved treatment outcomes and quality of life for patients. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. We are advancing a Phase 3 program for navacaprant, a novel once-daily oral kappa opioid receptor (“KOR”) antagonist that is being developed for the treatment of major depressive disorder (“MDD”), which we believe has the potential to provide significant advantages relative to the standard of care, if approved. We are also advancing NMRA-511, a highly selective, novel antagonist of the vasopressin 1a receptor (“V1aR”) being developed for the treatment of agitation…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income56-$241.2M in 2025+77% since 2022
-$300.0M-$200.0M-$100.0M02022: -$135.9M-$135.9M20222023: -$252.1M-$252.1M2023+86%2024: -$263.5M-$263.5M2024+5%2025: -$241.2M-$241.2M2025−8%
Net income56-$236.9M in 2025+81% since 2022
-$300.0M-$200.0M-$100.0M02022: -$130.9M-$130.9M20222023: -$235.9M-$235.9M2023+80%2024: -$243.8M-$243.8M2024+3%2025: -$236.9M-$236.9M2025−3%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Research and development$176.1M$200.9M
General and administrative$60.1M$62.5M
Acquired in-process research and development$5.0M$0
Total operating expenses$241.2M$263.5M
Loss from operations-$241.2M-$263.5M
Interest income$8.3M$19.9M
Interest expense-$3.2M$0
Other expense, net-$767.0K-$78.0K
Total other income$4.4M$19.9M
Net loss before income taxes-$236.8M-$243.6M
Provision for income taxes$130.0K$178.0K
Net loss-$236.9M-$243.8M
Unrealized gain (loss) on marketable securities-$62.0K$138.0K
Comprehensive loss-$237.0M-$243.6M
Net loss per share, basic-$1.45-$1.53
Net loss per share, diluted-$1.45-$1.53
Weighted-average shares outstanding, basic163.4M shares159.4M shares
Weighted-average shares outstanding, diluted163.4M shares159.4M shares

Compare Neumora Therapeutics, Inc. with another company

Leadership

Who has led Neumora Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Henry O. Gosebruch2023–2024
  2. Joshua Pinto2026–now

President

  1. Henry O. Gosebruch2023–2024
  2. Joshua Pinto2025–now

Chief financial officer

  1. Joshua Pinto2023–2024

Chief operating officer

  1. Carol Y. Suh2023–2024
2025
Board members and other officers (13)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerTamara Tompkins named Jan 3, 202326
  • DirectorKari Stefansson named Jan 3, 202326
  • DirectorMatthew Fust named Jan 3, 202326
  • DirectorRobert Nelsen named Jan 3, 202326
  • DirectorStacie Weninger named Jan 3, 202326

Timeline

  1. Aug 21, 2026New chief executive Joshua Pinto becomes CEO10
  2. Sep 14, 2023New chief executive Henry O. Gosebruch becomes CEO11

Filings

257 filings to the SEC since October 2021: 3 annual reports, 9 quarterly reports, 33 major events, 118 insider forms, 18 large holders, 1 private raises, 75 other. The latest 20:

  1. Aug 21, 2026144 EDGAR
  2. Aug 21, 20264 EDGAR
  3. Aug 21, 20264 EDGAR
  4. Aug 21, 20264 EDGAR
  5. Aug 21, 20264 EDGAR
  6. Aug 21, 20264 EDGAR
  7. Aug 20, 2026144 EDGAR
  8. Aug 19, 2026144 EDGAR
  9. Aug 19, 20264 EDGAR
  10. Aug 18, 2026144 EDGAR
  11. Aug 17, 2026144 EDGAR
  12. Aug 14, 202610-Q EDGAR
  13. Aug 14, 20268-K EDGAR
  14. Jul 27, 20268-K EDGAR
  15. Jun 15, 20268-K EDGAR
  16. May 29, 20264 EDGAR
  17. May 29, 20264 EDGAR
  18. May 29, 20264 EDGAR
  19. May 29, 20264 EDGAR
  20. May 29, 20264 EDGAR

The 257 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

62 open-market trades by officers, directors and large owners since October 2021: 36 buys and 26 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 21, 2026Aurora Daljit SinghSee RemarksSale41,608$1.60$66.4KForm 4
Aug 20, 2026Aurora Daljit SinghSee RemarksSale134,452$1.51$203.0KForm 4
Aug 19, 2026Aurora Daljit SinghSee RemarksSale61,918$1.65$102.2KForm 4
Aug 18, 2026Aurora Daljit SinghSee RemarksSale69,149$1.59$109.6KForm 4
Aug 17, 2026Aurora Daljit SinghSee RemarksSale146,706$1.50$220.3KForm 4
Feb 17, 2026Aurora Daljit SinghSee RemarksSale6,165$3.56$21.9KForm 4
Feb 17, 2026Pinto JoshuaPresident & CEOSale5,967$3.54$21.1KForm 4
Feb 17, 2026BERNS PAUL LSee RemarksSale9,819$3.51$34.5KForm 4
Feb 17, 2026Milligan Michael LeeSee RemarksSale1,436$3.57$5.1KForm 4
Nov 11, 2025Aurora Daljit SinghSee RemarksSale114,703$2.68$307.4KForm 4
Oct 27, 2025Burow KristinaDirectorBuy1,915,700$2.61$5.0MForm 4
Oct 27, 2025ARCH Venture Partners XII, LLC10% ownerBuy1,915,700$2.61$5.0MForm 4
Oct 27, 2025ARCH Venture Partners VIII, LLC10% ownerBuy1,915,700$2.61$5.0MForm 4
Feb 18, 2025BERNS PAUL LSee RemarksSale13,871$1.69$23.4KForm 4
Feb 18, 2025Milligan Michael LeeSee RemarksSale1,978$1.69$3.3KForm 4
Feb 18, 2025Aurora Daljit SinghSee RemarksSale8,565$1.68$14.4KForm 4
Feb 18, 2025Lenz Robert A.Head of R&DSale5,614$1.67$9.4KForm 4
Feb 18, 2025Pinto JoshuaPresident & CEOSale8,048$1.67$13.4KForm 4
Oct 18, 2024Fust Matthew KDirectorSale14,049$17.03$239.3KForm 4
Oct 17, 2024Fust Matthew KDirectorSale7,739$17.01$131.6KForm 4

All 62 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Sep 8, 2020Raised $474.4 million in a private offering of equity Form D: 124 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Siren, L.L.C.8,497,822$14.4M0.3%No change
BlackRock, Inc.7,791,869$13.2M0.0%+5,737,553
Softbank Group Corp.6,090,301$10.4M0.1%No change
Vanguard Capital Management LLC4,669,585$7.9M0.0%+777,692
MIC Capital Management UK LLP4,460,700$7.6M1.9%No change
Fmr LLC3,498,869$5.9M0.0%+211
WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST3,309,123$5.6M0.1%No change
Geode Capital Management, LLC2,607,289$4.4M0.0%+1,520,424
ICONIQ Capital, LLC2,559,090$4.4M0.1%No change
Two Sigma Investments, LP2,244,829$3.8M0.0%+208,137
Orbimed Advisors LLC2,139,882$3.6M0.1%New
Lunate Capital Ltd2,124,143$3.6M1.8%No change
Boxer Capital Management, LLC2,000,000$3.4M0.3%New
Johnson & Johnson1,849,445$3.1M0.4%No change
State Street Corp1,582,119$2.7M0.0%+1,183,400
Tudor Investment Corp Et Al1,356,147$2.3M0.0%+584,729
Ikarian Capital, LLC1,278,408$2.2M0.4%No change
Renaissance Technologies LLC1,262,304$2.1M0.0%−126,694
Affinity Asset Advisors, LLC1,070,651$1.8M0.1%New
Marshall Wace, Llp904,458$1.5M0.0%−290,852
Vanguard Portfolio Management LLC894,791$1.5M0.0%+709,955
Citadel Advisors LLC828,933$1.4M0.0%+485,347
Charles Schwab Investment Management Inc823,583$1.4M0.0%+307,401
Northern Trust Corp800,571$1.4M0.0%+603,690
Ensign Peak Advisors, Inc784,679$1.3M0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32